Wells Fargo Sticks to Its Hold Rating for Humana (HUM)
In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Humana, with a price target of $206.00. The company’s shares closed yesterday at $176.06.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Baxter is an analyst with an average return of -0.7% and a 45.45% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Humana, Centene, and CVS Health.
In addition to Wells Fargo, Humana also received a Hold from Barclays’s Andrew Mok CFA in a report issued yesterday. However, on February 17, Goldman Sachs maintained a Sell rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $32.52 billion and a GAAP net loss of $796 million. In comparison, last year the company earned a revenue of $29.21 billion and had a GAAP net loss of $693 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Humana price target lowered to $176 from $245 at Barclays
- Humana: Uncertain Margin Recovery and Star Rating Headwinds Drive Neutral ‘Hold’ Stance
- Humana price target lowered to $206 from $290 at Wells Fargo
- Humana price target lowered to $200 from $285 at Truist
- Humana price target lowered to $173 from $260 at TD Cowen
